Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China SFDA To Monitor Five Roche Drugs Tied To Adverse Reactions

This article was originally published in PharmAsia News

Executive Summary

China's State FDA plans to monitor five Roche drugs in the wake of a probe launched in Europe by the European Medicines Agency into the Swiss drug maker's failure to report adverse reactions and 15,000 possibly related deaths.

You may also be interested in...



Novartis CEO Backs Malaria Drug Against COVID-19

A coronavirus vaccine is some way off and until then, Vas Narasimhan, head of Novartis, is thinking that of the drugs being repurposed to treat COVID-19, hydroxychloroquine looks best places to provide the quickest benefit.

COVID-19 May Delay WHO’s Prequalification Of Devices, IVDs

Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.

COVID-19 May Delay WHO’s Prequalification Of Drugs, Devices, IVDs

Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.

Topics

Related Companies

UsernamePublicRestriction

Register

SC081583

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel